Eko is an AI-poweed digital health company that builds machine learning tools to fight heart disease.
Eko brings together advanced stethoscopes, patient and provider software, and AI-powered analysis—elevating the way they detect and monitor cardiovascular disease.
Eko was founded in 2013 by Connor Landgraf, Tyler Crouch and Jason Bellet. The company has its headquarter based in Berkeley, California.
Eko is building software, devices, and analysis algorithms for in-clinic heart disease screening, telemedicine, and monitoring patients at home. It is transforming cardiac care as we know it.
Eko has developed the first cardiac monitor to combine digital stethoscope and ECG technology both for in-clinic and at-home monitoring, which enables patients to seamlessly and consistently send cardiac data to their physicians. Its platform is used by tens of thousands of clinicians treating millions of patients at over 3,000 hospitals and providers around the world.
Eko is collaborating with medical device and pharmaceutical companies to create combinations of therapies and data to help personalize cardiac care. Eko will also grow its focus on clinical research, investing more in its collaborations with the Mayo Clinic, Northwestern Medicine, and UCSF.
Eko's Duo stethoscope captures both heart sounds and electrocardiogram readings, and is connected to an AI program that received an FDA clearance at the top of this year to detect the signs of atrial fibrillation and heart murmurs.
Eko is backed by ARTIS Ventures, DigiTx Partners, Highland Capital Partners, Questa Capital, NTT Venture Capital (NTTVC), 3M Ventures, Mayo Clinic, Seraph Group, XTX Ventures and others. The company raised $65M in Series C round on Nov 09, 2020. This brings Eko's total funding to $92.8M to date.